Castle Biosciences Inc. Common Stock (CSTL)

About CSTL

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invas…

Sector

Health Care

Industry

Medical Specialities

Employees

1,002

Website

castlebiosciences.com/

Fundamentals

1-day range

$32.8$34.28

Market cap

$928.40M

P/E (trailing)

—

P/E (forward)

-33.88

EPS (trailing)

$-0.65

Dividend yield

—

Beta

1.00

Avg. volume

403.0K

Forecasts

9 analyst ratings

Castle Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CSTL

  Castle Biosciences Inc. Common Stock

  $33.57

  ▼ 2.03%
  Market cap $928.40MP/E —
  $17.72$44.28
• LMRI

  Lumexa Imaging Holdings Inc. Common Stock

  $11.5

  ▼ 1.96%
  Market cap $1.08BP/E —
  $6.45$19.45
• TRUP

  Trupanion Inc. Common Stock

  $29.64

  ▼ 0.03%
  Market cap $1.09BP/E 57.51
  $21.16$46.98
• FRNM

  Freenome Inc. Common stock

  $14.77

  ▲ 5.95%
  Market cap $1.18BP/E —
  $9.97$14.34
• TLSI

  TriSalus Life Sciences Inc. Common Stock

  $4.85

  ▼ 1.62%
  Market cap $291.73MP/E —
  $2.2$7.95
• ACH

  Accendra Health Inc. Common Stock

  $1.22

  ▲ 0.83%
  Market cap $261.15MP/E —
  $0.9337$5.69
• YDES

  YD Bio Limited Ordinary Shares

  $4.8

  ▲ 24.03%
  Market cap $162.91MP/E —
  $1.7$25

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Castle Biosciences to Participate in Upcoming Investor Conferences
  Yahoo · 8/20/2026
• Castle Biosciences Approved For Dual Listing On Nasdaq Texas While Maintaining Primary Listing On Nasdaq Global Market
  benzinga · 8/17/2026
• Castle Biosciences Approved for Dual Listing on Nasdaq Texas
  Yahoo · 8/17/2026
• Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
  Yahoo · 8/13/2026
• BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44
  Benzinga · 8/3/2026
• Castle Biosciences, Inc. Q2 2026 Earnings Call Summary
  Yahoo · 7/31/2026
• Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ...
  Yahoo · 7/31/2026

• Tobin W. Juvenal · August 25, 2026 · Sale

  9.1K @ $35.04
• Kristen M. Oelschlager · August 25, 2026 · Sale

  5.2K @ $34.64
• Kristen M. Oelschlager · August 25, 2026 · Sale

  7.2K @ $34.26
• Kristen M. Oelschlager · August 24, 2026 · Sale

  12.2K @ $33.69
• Derek J. Maetzold · August 5, 2026 · Option Exercise

  2.5K @ $2.39
• Derek J. Maetzold · August 5, 2026 · Sale

  473 @ $30.68
• Derek J. Maetzold · August 5, 2026 · Sale

  556 @ $30.68
• Derek J. Maetzold · August 5, 2026 · Sale

  2.5K @ $30.68
• Derek J. Maetzold · August 4, 2026 · Option Exercise

  20.4K @ $2.39
• Derek J. Maetzold · August 4, 2026 · Sale

  4.1K @ $31.34
• Derek J. Maetzold · August 4, 2026 · Sale

  4.8K @ $31.34
• Derek J. Maetzold · August 4, 2026 · Sale

  11.9K @ $31.34
• Derek J. Maetzold · August 4, 2026 · Sale

  2.9K @ $30.79
• Derek J. Maetzold · August 4, 2026 · Sale

  3.4K @ $30.79
• Derek J. Maetzold · August 4, 2026 · Sale

  8.4K @ $30.79

Institutional Ownership

March 31, 2026

Total shares held

26.46M

Total value held

$626.93M

Institutional holders

179